GlassScriptPhysician profile
Thomas J Cipolla
NPI 1992860282
$23,274.93
in general payments reported to CMS, 2019-2025
55 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,422 · 2022: $3,609 · 2023: $8,090 · 2024: $4,854 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,244 · Honoraria: $7,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,243.80 |
| Honoraria | $7,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $8,169.45 | 2022-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Abbvie INC. | $2,018.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,819.57 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,608.00 | 2021 | |
| Pfizer INC. | $772.41 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.37 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $770.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $616.88 | 2021-2025 | Krystexxa, Repatha, Evenity |
| Novo Nordisk INC | $548.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $523.67 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Horizon Therapeutics Plc | $354.75 | 2021-2022 | |
| Amarin Pharma, INC. | $351.48 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $348.16 | 2023-2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $327.19 | 2022-2023 | Eliquis, Empliciti, Camzyos |
| Kowa Pharmaceuticals America, INC. | $287.37 | 2021-2023 | Seglentis, Livalo |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $284.66 | 2022-2023 | Opzelura |
| Daiichi Sankyo INC. | $250.71 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $248.23 | 2022-2025 | |
| Almatica Pharma LLC | $243.52 | 2021-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $240.96 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $233.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.31 | 2021-2022 | |
| Ardelyx, INC. | $208.97 | 2024-2025 | Ibsrela |
| Intuity Medical INC | $202.70 | 2022 | |
| Abbott Laboratories | $189.11 | 2021-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $188.85 | 2021-2025 | Contrave, Nexletol, Nexlizet |
| Exact Sciences Corporation | $179.70 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $147.38 | 2022-2025 | Verquvo, Belsomra, Lagevrio |
| Novartis Pharmaceuticals Corporation | $120.09 | 2021-2024 | |
| Renalytix Ai, INC. | $92.40 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Corcept Therapeutics | $88.52 | 2023-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $86.44 | 2021-2022 | |
| Esperion Therapeutics, INC. | $81.72 | 2021-2024 | Nexletol |
| Ascensia Diabetes Care US INC. | $72.59 | 2023 | |
| Lundbeck LLC | $69.04 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $56.02 | 2025 | Symbravo |
| Depuy Synthes Sales INC. | $51.26 | 2022-2024 | Orthovisc |
| Otsuka America Pharmaceutical, INC. | $50.58 | 2023-2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $49.49 | 2023 | Lyvispah |
| Dexcom, INC. | $39.93 | 2022-2023 | Dexcom G6 Transmitter |
| Cvrx, INC. | $32.14 | 2025 | Barostim Neo System |
| Shield Therapeutics INC | $24.67 | 2023 | Accrufer |
| Ani Pharmaceuticals, INC. | $23.88 | 2025 | Purified Cortrophin Gel |
| Antares Pharma, INC. | $23.29 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.36 | 2025 | Voquezna |
| Vivus LLC | $20.26 | 2021 | |
| Cequr Corporation | $20.22 | 2022 | |
| Astellas Pharma US INC | $19.86 | 2023 | Veozah |
| Evofem Biosciences, INC. | $19.58 | 2022 | |
| Bausch Health US, LLC | $19.15 | 2022 | |
| Clarus Therapeutics INC. | $17.00 | 2021 | |
| Phadia US INC. | $16.02 | 2023 | Immunocap |
| Genentech USA, INC. | $15.20 | 2021 | |
| Vistapharm, INC. | $13.15 | 2021 | |
| Echosens North America, INC. | $9.96 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cipolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.